We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Canadian drugmaker Apotex wants legal protection from patent
infringement liabilities related to the manufacturing and marketing of ranitidine hydrochloride, a generic version of GlaxoSmithKline's (GSK) Zantac, according to a complaint filed in U.S. federal court last week.
The Novartis Institute for Tropical Diseases (NITD) has announced the launch of a new clinical research initiative in Indonesia that will further expand the capabilities of the Singapore-based institute to conduct research on tuberculosis (TB), dengue fever and malaria.
The Medicines for Malaria Venture (MMV) and Shin Poong Pharm have begun recruiting patients to participate in a pivotal clinical trial of Pyramax (pyronaridine artesunate), a new artemisinin-based combination treatment for malaria.
The invalidation of a key patent held by Pfizer could open the door to the manufacturing and marketing of atorvastatin tablets, a generic version of Pfizer's blockbuster cholesterol-lowering drug, Lipitor.
The Association of the British Pharmaceutical Industry (ABPI) has released new figures showing that there were no personal assaults by animal extremists on British drug company employees in 2006.
A lawsuit filed by Novartis against the Indian patent office is set to go to court today in Chennai, India, despite the protests of humanitarian organizations.
Foamix, headquartered in Israel, announced it has entered a worldwide license agreement with Dr. Reddy's Laboratories to develop a prescription emollient foam for the treatment of psoriasis.
Sanofi pasteur, the vaccines arm of sanofi-aventis, announced that the FDA's Vaccines and Related Biological Products Advisory Committee decided that the company's pentavalent combination vaccine is safe and efficacious for use in pediatric patients.
Astellas Pharma and Pfizer Japan have announced they have received Japanese regulatory approval for Celecox, a non-steroidal anti-inflammatory drug, for treating the pain and inflammation of rheumatoid arthritis and osteoarthritis.